Daiichi Nets Novel HER-3 Antibody With U3 Acquisition
Daiichi Sankyo will acquire the privately held German biotech U3 Pharma in a €150 million ($233.9 million) deal that includes a novel HER-3 receptor antagonist partnered with Amgen
Daiichi Sankyo will acquire the privately held German biotech U3 Pharma in a €150 million ($233.9 million) deal that includes a novel HER-3 receptor antagonist partnered with Amgen